Neurocrine Biosciences Inc (NAS:NBIX)
$ 141.555 -0.445 (-0.31%) Market Cap: 14.25 Bil Enterprise Value: 13.61 Bil PE Ratio: 39.01 PB Ratio: 5.97 GF Score: 89/100

Neurocrine Biosciences Inc at Needham Neuroscience Forum (Virtual) Transcript

Mar 16, 2022 / 05:50PM GMT
Release Date Price: $92.16 (+1.21%)
Ami Fadia
Needham & Company, LLC, Research Division - Research Analyst

Good afternoon, everyone. Welcome to the next session with Neurocrine Bioscience. Kyle, thank you so much for taking out the time to join today.

For those who are not very familiar with the company and with Kyle, Kyle is the Chief Business Development and Strategy Officer at Neurocrine. He's been with the company since 2011 and has been responsible for many of the business development collaborations that the company has and would love to spend the session that we have with Kyle to go over some of the many pipeline initiatives that the company is undertaking. But perhaps before we start, if I could ask Kyle to just give us some opening remarks, and we'll jump right into questions. And the audience can send me questions via the chat as well.

Kyle W. Gano
Neurocrine Biosciences, Inc. - Chief Business Development and Strategy Officer

Great. Thanks, Ami, and welcome to everyone here for the conference. It's a great lineup today. I'm just going over the agenda. It looks like a full

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot